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Background. Although relapse in psychosis is common, a small proportion of patients 
will not relapse in the long term. We examined the proportion and predictors of patients 
who never relapsed in the 10 years following complete resolution of positive symptoms 
from their first psychotic episode. 
Method. Patients who previously enrolled in a 12-month randomized controlled trial on 
medication discontinuation and relapse following first-episode psychosis were followed 
up after 10 years. Relapse of positive symptoms was operationalized as a change from 
a Clinical Global Impression scale positive score of <3 for at least three consecutive 
months to a score of ≥3 (mild or more severe). Baseline predictors included basic 
demographics, premorbid functioning, symptoms, functioning, and neurocognitive 
functioning.  
Results. Out of 178 first-episode patients, 37 (21%) never relapsed during the 10-year 
period. Univariate predictors (P≤0.1) of patients who never relapsed included a duration 
of untreated psychosis (DUP) ≤30 days, diagnosed with non-schizophrenia spectrum 
disorders, having less severe negative symptoms, and performing better in logical 
memory immediate recall and verbal fluency tests. A multivariate logistic regression 
analysis further suggested that the absence of any relapsing episodes was significantly 
related to better short-term verbal memory, shorter DUP, and non-schizophrenia 
spectrum disorders.  
Conclusions. Treatment delay and neurocognitive function are potentially modifiable 
predictors of good long-term prognosis in first episode psychosis. These predictors are 
informative in that they can be incorporated into an optimum risk prediction model in the 
future, which would help with clinical decision making regarding maintenance treatment 
in first-episode psychosis.  
Key words: schizophrenia, early psychosis, relapse, long-term follow-up, predictors 
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Introduction 
Relapse constitutes a major problem in managing patients with psychotic disorders, with 
up to 80% of patients relapsing within five years following illness onset (Robinson et al. 
1999). Meta-analysis shows that the risk of relapse was up to over 90% by two years 
following first episode psychosis (Zipursky et al. 2014). Relapse can cause substantial 
or even irreversible damage, particularly in young patients during the most productive 
period of their lives. Maintenance antipsychotic treatment for a considerable period of 
time is often required to prevent symptom recurrence. In first episode schizophrenia 
patients whose antipsychotics are discontinued (stepwise), those responding well to 
antipsychotics treatment had a greater risk of relapse (Gaebel et al. 2016). Longitudinal 
studies have revealed that around 20% of patients will not relapse after their first 
episode of psychosis (Shepherd et al. 1989; Linszen et al. 2001). However, not much 
long-term data exist to help characterize this subgroup of patients who do not relapse. 
The successful identification of factors predicting this subgroup can help tailor a better 
treatment approach in relapse prevention, in conjunction with maintenance 
antipsychotic treatment.  
Few studies have examined the proportion and predictors of first-episode 
psychosis (FEP) patients who do not relapse in the long term. In a naturalistic follow-up 
study, Alverez-Jimenez et al. (2011) found that 16.5% of FEP patients did not relapse 
during the 7.5-year follow-up period, and that they are characterized by having a 
duration of untreated psychosis (DUP) <60 days, displaying more rapid response to 
antipsychotic treatment, and being less likely to have parental loss at baseline (Alverez-
Jimenez et al. 2011). However, other important predictors such as neurocognitive 
functioning were not explored. The study has a dropout rate of up to 66% at follow-up, 
rendering generalizability to all psychosis patients difficult. Furthermore, relapse was 
retrospectively recalled by patients during the follow-up assessment, which may have 
introduced a bias towards recalling only more severe episodes and ignoring less 
“dramatic” ones, resulting in an underestimated rate of relapse-free patients. In another 
study of FEP patients who were randomized to an 18-month dose-reduction trial 
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following symptomatic remission, Wunderink et al. (2013) found that 34.9% of patients 
did not relapse during a 7-year period, but no predictors of relapse were reported.  
This was a 10-year follow-up study of patients who were previously enrolled in a 
12-month randomized controlled trial (RCT) on medication discontinuation and relapse 
following complete resolution of positive symptoms from FEP (Chen et al. 2010). Data 
from the RCT showed that the Kaplan-Meier estimate of the risk of relapse at 12 months 
nearly doubled in the placebo group (79%) compared to the maintenance group (41%) 
(Chen et al. 2010). In this 10-year follow-up study, we examined (1) the proportion of 
patients who did not relapse over the 10 years, (2) the potential baseline predictors of 
not relapsing, including socio-demographic information, symptoms, functioning, as well 
as neurocognitive functions, and (3) the clinical and neurocognitive outcome correlates 
of this subgroup of relapse-free patients.  
 
Methods 
Study design  
Across the Hong Kong Special Administrative Region of approximately seven million 
people, specialized teams of the Early Assessment Service for Young People with 
Psychosis (EASY) provide assessment and treatment for patients with FEP (Chen, 
2004). Between 2003 and 2005, 178 FEP patients with complete resolution of positive 
symptoms were randomized to receive either quetiapine (400mg/d) or placebo for 12 
months (ClinicalTrials.gov Identifier: NCT00334035) (Chen et al. 2010). Upon 
completion of the 12-month RCT, patients continued to receive naturalistic regular care 
at general adult out-patient psychiatric clinics. Between November 2013 and December 
2014, this cohort was followed up prospectively after 10 years to assess their clinical 
outcomes, including persistent positive symptoms, requirement of taking clozapine, and 
suicide (ClinicalTrials.gov Identifier: NCT01926340) (Hui et al. 2018). The current study 
focused on examining the long-term outcome of relapse.  
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This study was approved by the institutional review boards at each site, and 
carried out in accordance with Good Clinical Practice and the Declaration of Helsinki. All 
participants provided written informed consent.  
 
Participants 
Included participants had a diagnosis of schizophrenia or non-affective psychosis 
(schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or 
psychosis not otherwise specified) (DSM-IV) (APA, 1994), were aged 18-65 years, had 
been treated with antipsychotic drugs continuously for at least one year, had good 
medication compliance (missed <50% of their medication, missed <50% of their clinic 
visits, or had no history of medication discontinuation), and had no history of relapse 
(defined as no increase of positive symptoms of psychosis requiring admission to 
hospital or adjustment of medication). Patients had to be free of positive symptoms of 
psychosis for at least 8 weeks as assessed using (1) five Positive and Negative 
Syndrome Scale (PANSS; Kay et al. 1987) items: delusions, conceptual 
disorganization, hallucinations, suspiciousness, unusual thought content, and (2) the 
Clinical Global Impressions (CGI) scale (Guy, 1976) with a score of 2 (borderline or 
questionable) or less. Exclusion criteria were diagnosis of drug-induced psychosis, 
treatment with clozapine, mood stabilizing medications (lithium, valproate or 
carbamazepine) or depot medication, and a risk of suicide or violence.  
Diagnosis at follow-up was determined using the best-estimate consensus 
approach with all sources of information available, including the validated Chinese 
version of the Structured Clinical Interview for DSM-IV (So et al. 2003), medical records, 
and history from research assistants during face-to-face interviews. Two experienced 
psychiatrists reached a consensus in the diagnosis for each subject. 
 
Outcome measures  
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To obtain the outcome measures, research assistants at Master’s level carried out 
direct face-to-face interviews with patients at 10 years, and extracted monthly data 
using medical records and the Health Authority Clinical Management System over the 
entire follow-up period. Raters were blinded to the randomized trial assignment and the 
follow-up status of the participants.     
Relapse was defined as the re-emergence or exacerbation of positive symptoms, 
as operationalized by a change from CGI positive (Haro et al. 2003) scores <3 for at 
least three consecutive months to a score of ≥3 (mild or more severe) (Haro et al. 2011; 
Chan et al. 2015). Relapse was assessed monthly using medical record review ratings 
of CGI positive symptom severity scores from the start of the RCT until the end of the 
10 years in all patients. The CGI-positive has a rating from 1 (normal), 2 (borderline), 3 
(mild), to 7 (most severely ill). For each relapse episode, we recorded the start and end 
dates (duration), and whether the event required hospitalization. Weekly consensus 
meetings were conducted among a clinician and research assistants during the data 
collection period for quality assurance and for resolving ambiguity in ratings. To ensure 
consistency in ratings, the CGI-positive was rated from eight independent medical 
records (i.e. not those cases recruited into the current study). Good agreement was 
found among the three raters, with an intra-class correlation of 0.7. 
To validate the definition of relapse using CGI-positive, we compared the 
concordance between the relapses derived using CGI-positive with those using the 
“remission/relapse” definition in the abovementioned inclusion criteria. The latter was 
operationalized as meeting the following criteria using medical record reviews: (1) at 
least one of the following in the PANSS scale: delusions >3, conceptual disorganization 
>4, hallucinations >3, suspiciousness >5, or unusual thought content >4, and (2) scores 
>3 and >5 in the CGI severity of symptoms and CGI improvement scales respectively. 
There was excellent agreement between the two relapse definitions (κ=0.842, P<0.001).  
Instead of targeting a few specific positive symptoms in defining relapse (as is 
the case in PANSS), the current CGI-positive definition focuses on the overall severity 
of the patient’s positive symptoms at the time of assessment. This approach is more 
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relevant and applicable to data extraction using medical record reviews, given that not 
all clinicians provide detailed psychopathology, but instead provide an overall 
description of the psychotic symptoms of patients. In addition, compared to 
retrospective recall of relapses from patients over the past 10 years (Alverez-Jimenez et 
al. 2011), the current medical record review of positive symptoms of relapse using CGI-
positive would minimize the chance of underestimation of any relapse episodes, and 
ensures that relapse of positive symptoms to a mild or more severe level are all 
included.  
Other outcome measures included information on marital status, diagnosis, 
antipsychotic treatment, and medication adherence. Positive and negative symptoms 
were assessed using the PANSS, the Scale for the Assessment of Positive Symptom 
(SAPS; Andreasen, 1984), and the Scale for Assessment of Negative Symptoms 
(SANS; Andreasen, 1983). Depressive symptoms were assessed using the Calgary 
Depression Scale for Schizophrenia (CDSS; Addington et al. 1992). Insight into the 
illness was measured by the abridged Scale to Assess Unawareness of Mental Disorder 
(SUMD; Amador et al. 1994). Side effect was assessed with the Simpson-Angus Scale 
(SAS; Simpson et al. 1970), the Abnormal Involuntary Movement Scale (AIMS; Guy, 
1976), the Barnes Akathisia Rating Scale (BARNS; Barnes, 1989), and the Udvalg for 
Kliniske Undersøgelser (UKU; Lingjaerde et al. 1987). Functioning was assessed using 
the Social and Occupational Functioning Assessment Scale (SOFAS; Goldman et al. 
1992) and the Strauss and Carpenters’ scale (Strauss & Carpenter, 1972). Direct 
interviews were performed with 142 out of the 178 patients at 10 years. 
 
Baseline predictor measures 
All potential baseline predictors were evaluated at entry to the RCT, where all patients 
had complete resolution of positive symptoms for at least one year following their first 
episode of psychosis. Baseline variables included gender, age, years of education, 
employment, marital status, diagnosis (schizophrenia spectrum disorders: 
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schizophrenia, schizophreniform disorder and schizoaffective disorder vs. non-
schizophrenia spectrum disorders: brief psychotic disorder and psychosis not otherwise 
specified), and treatment received during the RCT (quetiapine vs. placebo). 
Premorbid functioning was assessed using the Premorbid Adjustment Scale 
(PAS; Cannon-Spoor et al. 1982). The same symptoms, insight and functioning 
assessments (see above in outcome measures) were used. DUP was assessed using 
the Interview for the Retrospective Assessment of the Onset of Schizophrenia (IRAOS; 
Häfner et al. 1992). 
Neurocognitive functions assessed were as follows: Information, Arithmetic, Digit 
Span (forward and backward), Digit Symbol, Block Design, Trail Making Test (response 
time difference between the two tasks), Letter Number Span (the highest level attained), 
Logical Memory Test (total number of correct immediate and delayed recalls), Visual 
Patterns Test (the highest level attained), Semantic Fluency Test (total number of 
correct animals reported in one minute), and the Modified Wisconsin Card Sorting Test 
(total number of perseveration errors). The total number of times the patient blinked 
during two minutes of relaxation was also recorded.  
 
Statistical analysis 
All statistical analyses were carried out using IBM® SPSS® Version 24.0. To examine 
the potential baseline predictors (independent variables) for patients who never 
relapsed over the 10 years (dependent variable: never relapsed=1, relapsed=0), 
univariate binary logistic regression analysis was used. Univariate variables with a P 
value of ≤0.1 were identified. To avoid multicollinearity, only one score for each 
performance test was chosen; for example, in the Logical Memory Test, immediate 
memory recall was used instead of both immediate and 30-minute delayed recall 
because the two are highly correlated. The remaining identified predictors were entered 
into a multivariate binary logistic regression model using forward selection with a P 
value of ≤0.05 indicating significance.  
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Among patients who completed the face-to-face interview assessments after 10 
years, the outcome correlates of whether the patient relapsed over the 10 years were 
explored using the independent t-test for parametric continuous variables, the Chi-
squared (χ²) test for categorical variables, and the Mann-Whitney U test for non-
parametric continuous variables. To handle the problem of multiple testing, the false 
discovery rate (FDR) (q-value) of 10% with the Benjamini-Hochberg procedure was 
used. 
 
Results 
Basic demographics 
The study cohort was followed up for a median of 9.4 years (interquartile range, IQR 
8.5-10.4) since the start of the RCT, and a median of 11.3 years (IQR 10.3-12.2) since 
the patient’s first episode of psychosis. Of the 178 patients in the original RCT, 142 
(80%) were successfully traced and interviewed, 28 (16%) declined assessment, 6 (3%) 
committed suicide, and 2 (1%) were unable to be contacted.  
Table 1 shows the baseline (i.e., entry into the RCT) demographics and 
treatment characteristics during the follow-up of all patients. Forty-five percent of 
patients were male. They had a mean age of 24.2 years, and received education for a 
mean of 11.8 years. The majority of them (70%) were employed. There were no 
statistical baseline differences between those who relapsed and never relapsed in terms 
of gender, age, years of education, employment, marital status, and whether they 
received maintenance treatment or placebo during the randomized trial. The 
antipsychotics medication received over the follow-up period were similar in relapsers 
and non-relapsers. 
[Table 1] 
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Relapse over the 10 years 
Over the 10 years, 37 of 178 (21%) patients never relapsed following complete 
resolution of their positive symptoms from a first episode. In other words, relapse was 
observed in 141 of 178 (79%) patients, where 68 of 141 (48%) experienced one 
relapse, 44 of 141 (31%) experienced two relapses, 16 of 141 (11%) experienced three 
relapses, and the remaining 13 of 141 (9%) experienced four or more relapses. The 
mean number of relapse episodes was 1.5 (SD=1.4, range 0-11).  
 Among the 141 relapsers, the mean aggregate time spent in the first relapse was 
5.4 (SD=12.6) months, and 55 (39%) of the relapsed patients required hospitalization. 
As for the timing of relapse, 85 of 141 (60%) patients relapsed in the first year after 
complete resolution of positive symptoms, 24 (17%) in the second year, 12 (6%) in the 
third year, 7 (5%) in the fourth year, and 4 (3%) in the fifth year.  
Univariate predictors of never relapsing 
Table 2 shows the univariate predictors of relapse at 10 years which had a P value of 
≤0.1. Patients who never relapsed were less likely to be diagnosed with schizophrenia 
spectrum disorders, more likely to have a DUP ≤30 days, had less severe negative 
symptoms at baseline (especially blunted affect), had better performance in the Logical 
Memory (immediate and delayed recall) and Verbal Fluency Tests at baseline than 
those who relapsed. Other baseline predictors explored, including basic demographics, 
treatment received during the RCT (quetiapine or placebo), DUP, premorbid and 
baseline functioning, were not statistically significant in predicting relapse.  
[Table 2] 
To avoid the problem of multicollinearity, the single variable with the smaller P 
value in each assessment was selected for inclusion into the multivariate regression 
model. They included baseline diagnosis, DUP ≤30 days, SANS sum of all items, logical 
memory (immediate recall), and verbal fluency (correct recall).  
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Multivariate predictors of never relapsing 
The multivariate logistic regression analysis suggested that patients who did not relapse 
over the 10 years were less likely to be diagnosed with schizophrenia spectrum 
disorders (Odds ratio, OR=0.23, 95% CI 0.13 to 0.90, P=0.030), more likely to have a 
DUP ≤30 days (OR=4.60, 95% CI 1.65 to 12.84, P=0.004), and performed better in the 
logical memory immediate recall at baseline (OR=1.10, 95% CI 1.00 to 1.22, P=0.050) 
(Table 3). The model explained 26.9% (Nagelkerke R2) of the variance, with an overall 
correct classification of 81.8%.  
[Table 3] 
 
Outcome correlates of never relapsing  
As shown in Table 4, more non-relapsers were married/in a stable relationship and 
diagnosed with non-schizophrenia spectrum disorders at 10 years. They took a lower 
mean dose of daily antipsychotics chlorpromazine equivalent over the follow-up period. 
More of them were able to stop taking antipsychotics in the 2 years prior to follow up, 
reported having fewer medication side effects (BARNS, UKU neurologic, and UKU 
others), and had a lower BMI than those who relapsed. Non-relapsers also had better 
social and occupational functioning at 10 years (higher SOFAS score, higher SCS 
score, and had more months in open employment over the 2 years prior to follow up). 
All these findings remained significant at a FDR rate (q value) of 10%. When the FDR 
rate was set to 5%, the significant variables included medication discontinuation in the 
past 2 years, diagnosis with schizophrenia spectrum disorders, UKU neurologic side 
effect, BARNS side effect, BMI, and being married/in a stable relationship.  
[Table 4] 
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Discussion 
To date, this is the first 10-year follow-up study examining the proportion and predictors 
of patients who did not experience psychotic relapse in the 10-year period following 
complete resolution of positive symptom from FEP. Our data suggested that the 
proportion of relapse-free patients after 10 years was 21%. This subgroup of relapse-
free patients were characterized by being less likely to be diagnosed with a 
schizophrenia spectrum disorder, having a DUP ≤30 days, and having better short-term 
verbal memory following their first episode. These observed differences between 
relapsers and non-relapsers were unlikely to be a result of the difference in 
antipsychotic medications received over the ten years. Such findings not only provide 
an updated perspective on the characterization of patients who did not relapse after 10 
years, but also expand the predictors of not relapsing to include a neurocognitive 
dimension. Identification of potentially modifiable predictors of not relapsing would 
facilitate timely intervention at the early stages of the illness, and thus produce better 
long-term outcome.  
 
Relapse rates over the 10 years 
Consistent with previous longitudinal studies (Shepherd et al. 1989; Linszen et al. 
2001), the proportion of relapse-free patients in this study was 21%. This was slightly 
higher than the rate of 16.8% reported in a different 7.5-year follow-up study of FEP 
(Alverez-Jimenez et al. 2011). We believe the discrepancy could well be reflecting the 
differences in the study populations, as the previous study included FEP patients under 
a naturalistic setting, whereas the current study focused on FEP patients who were 
entirely free from any psychotic symptoms and had received maintenance treatment for 
at least one year under a controlled study setting. This might explain why our good 
prognostic first-episode cohort would have a slightly higher proportion of relapse-free 
patients after 10 years.  
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It was interesting to note that in a similar follow-up study of FEP patients who had 
been randomized to either dose reduction or maintenance treatment for 18 months 
following stabilization, the proportion of relapse-free patients at seven years was up to 
35% (Wunderink et al. 2013). One reason for this higher rate of relapse-free patients in 
the Dutch study may be related to their use of a dose reduction arm instead of complete 
medication discontinuation (as in our case) during the initial clinical trial. The fact that a 
lower relapse rate in the initial trial was found in the Dutch study (43% in the dose 
reduction group; Wunderink et al. 2007) when compared to the Hong Kong study (79% 
in the discontinuation group; Chen et al. 2010), could explain the higher proportion of 
patients in the Dutch study who did not subsequently relapse in the long term. 
 
Neurocognition and relapse 
More research has begun to explore the link between neurocognitive dysfunction and 
relapse in psychosis, as neurocognitive function is a potentially modifiable factor. 
Shorter-term follow-up studies have identified baseline memory function (Verdoux et al. 
2000), delayed visual reproduction (Verdoux et al. 2000), Wisconsin Card Sorting Test 
perseverative errors (Chen et al. 2005), Trail Making Test-B (Wolwer et al. 2008), 
working memory, and verbal learning (Rund et al. 2007) to be predictive of relapse in 
psychosis. More recently, visual working memory deterioration was found to occur 
preceding a psychotic relapse (Hui et al. 2016).  
Here, we presented a novel finding that patients with better short-term verbal 
memory (immediate logical memory) at baseline were more likely to be relapse-free 
after 10 years. Similarly, Rund et al. (2016) have found that remitted patients who did 
not relapse during the first year had better neurocognitive function at 10 years than 
those with unstable remission or continuously psychotic during the first year, implying a 
link between early relapse and long-term cognitive outcome. Our data further clarified 
that early neurocognitive functioning is also associated with subsequent relapse status 
after 10 years.  
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DUP and relapse 
DUP is an important marker for delay in first effective psychiatric treatment. The 
identification of DUP as a predictor is of high clinical interest due to its ability to improve 
clinical outcome and reduce costs, since considerable long-term studies (with follow-up 
durations >7.5 years) have confirmed the negative impact of a long DUP on overall 
symptomatic outcome (Thara & Eaton, 1996; Bottlender et al. 2003; White et al. 2009; 
Tang et al. 2014). In this study, the status of non-relapse at 10 years was predicted by 
DUP ≤30 days. This is consistent with previous short-term follow-up studies (Crow et al. 
1986; Larsen et al. 2000), as well as the longer-term follow-up study of FEP (Alverez-
Jimenez et al. 2011).  
Given how there is no standardized method of handling the positively skewed 
DUP data, the adoption of the threshold value of DUP ≤30 days for categorizing 
subgroups made no assumption about the linear relationship between DUP and 
outcome. The threshold was also based on our local study, which showed that a DUP 
as short as 30 days is sufficient to demonstrate a significant negative impact on the 
remission outcome at 13 years in Chinese patients with FEP (Tang et al. 2014).  
 
Schizophrenia spectrum disorders and relapse 
Although it is widely known that a diagnosis of schizophrenia (as opposed to other 
psychoses) is associated with poorer outcome, the exact relationship between a 
diagnosis of schizophrenia and the short-term outcome of relapse remains contentious: 
for example, while one study found that schizophrenia patients who discontinued 
medication experience more relapses (Hui et al. 2013), other short-term follow-up 
studies have not found such a relationship (Crow et al. 1986; Lenior et al. 2005). On the 
other hand, the available evidence for a diagnosis of schizophrenia and the long-term 
outcome of relapse appears more consistent. Alverez-Jimenez et al. (2011) found 
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schizophrenia spectrum disorders (including schizophrenia, schizophreniform, 
schizoaffective, delusional, psychotic disorder not otherwise specified, and brief 
psychotic disorders) to be a significant univariate predictor of relapse at 7.5 years in 
FEP. In our 10-year study, we also found that those diagnosed at baseline with 
schizophrenia spectrum disorders (including schizophrenia, schizoaffective disorder, 
and schizophreniform disorder) were more likely to predict relapse.  
Given that a non-schizophrenia diagnosis and a DUP ≤30 days were found to be 
significant multivariate predictors of not relapsing, one might ask if these relapse-free 
patients were composed of individuals diagnosed with brief psychotic disorders in the 
first place. Out of 37 relapse-free patients, 18 (49%) were diagnosed with schizophrenia 
spectrum disorders, 10 (27%) diagnosed with psychosis not otherwise specified, and 
the remaining 9 (24%) diagnosed with brief psychotic disorder. The postulation that 
relapse-free patients were simply brief psychotic disorder cases with a shorter DUP is 
therefore unlikely.  
 
Limitations  
Owing to the restrictive inclusion criteria used (must have complete resolution of 
positive symptoms, good compliance, and been on maintenance medication for at least 
1 year after stabilization), the employment rate for our cohort at baseline was up to 
70%. Therefore, our cohort may not have been representative of all FEP patients. Given 
that the cohort must have had good medication compliance to enter the study before 
randomization to either maintenance treatment or placebo, it is not possible to explore 
the effect of medication non-compliance at baseline on relapse after 10 years. However, 
exploratory analyses on the initially five yearly medication compliance data extracted 
from medical records did not predict relapse. Further, the existing medication 
compliance data do not allow for the differentiation between relapses that occur in 
patients receiving ongoing treatment and those relapsing following medication 
discontinuation over the ten years. A more rigorous adherence assessment to identify 
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the temporal relationship to the relapse events would be helpful. We did not include 
measures on expressed emotion and stress, which may be relevant for relapse 
prediction and long-term prognosis of first episode psychosis. In addition, as the 
prevalence of substance misuse is relatively low in the Hong Kong population, those 
with significant alcohol or other substance misuse in the past 3 months were excluded. 
Such exclusion enabled a more homogeneous sample, but leaves results incomparable 
to those of Western cohorts. It should also be noted that relapse in this study referred to 
the re-emergence or exacerbation of positive symptoms to a mild or more severe level, 
which may be different from the rest of the literature. Although whether patients were 
randomized to quetiapine/placebo during the RCT was not significantly different 
between relapsers and non-relapsers, we cannot entirely discard the effect of 
randomization on subsequent relapse after 10 years. 
 
Clinical and research implications 
The existing prediction model had 27% of the variance explained. Testable and 
modifiable predictors of relapse such as DUP and cognitive function would be an 
important addition to the long-term management of patients with psychosis and could 
lead to effective strategies for relapse prevention. In a study of Chinese FEP patients in 
Hong Kong, previous family experiences and knowledge about psychiatric illnesses 
were found to be important factors related to a shorter DUP (Chen et al. 2005). This is 
particularly relevant to our Chinese patients, because a predominant proportion of them 
live with their families, and the decision to seek help heavily relies on immediate family 
members. Early detection and psychoeducation programs could target family members 
to increase their awareness of signs related to onset of psychosis during the prodromal 
period, thereby shortening the delay to receiving timely psychiatric treatment.  
The identification of neurocognitive function as marker for long-term clinical 
outcome such as relapse is important, because neurocognitive markers are clearly 
defined, relatively easy to administer, reproducible, and can objectively be measured. 
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There is now a growing focus in improving the outcome of psychosis by cognitive 
enhancement through remediation and other non-invasive approaches. More research 
is needed to replicate this finding before this marker is used as a screening tool for 
relapse in actual clinical practice.  
Finally, we found that never relapsing during the 10-year period was associated 
with various clinical correlates, including an increased likelihood of being able to stop 
taking medication in the two years prior to follow-up, being married/in a stable 
relationship, having fewer medication side effects, and having a lower BMI. Shortening 
the delay to receiving timely psychiatric treatment and treatment for cognitive 
symptoms, especially among patients with schizophrenia spectrum disorders, thus 
appears to be important for improving the long-term clinical outcome of relapse.  
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Table 1. Basic demographics and treatment characteristics for non-relapsers, 
relapsers, and all patients. 
 
 
Non-
relapsers 
(n=37) 
Relapsers 
(n=141) 
All patients 
(n=178) 
P 
value 
Baseline variables     
  Male; n (%) 18 (49) 62 (44) 80 (45) 0.611 
  Age, years; mean (SD) 23.8 (5.9) 24.3 (6.5) 24.2 (6.4) 0.685 
  Education, years; mean (SD) 11.4 (2.4) 12.0 (2.9) 11.8 (2.8) 0.321 
  Employed; n (%) 30 (81) 97 (69) 127 (71) 0.141 
  Married/stable;a n (%) 5 (14) 10 (7) 15 (9) 0.238 
  On placebo during the 
randomized trial; n (%) 
17 (46) 72 (51) 89 (50) 0.579 
Naturalistic antipsychotics 
treatmentb 
    
  Duration, months; mean (SD) 112.2 (11.4) 111.9 (18.5) 112.0 (17.2) 0.928 
  Cumulative antipsychotic 
dose, mg/dayc 
414.9 
(259.9) 
548.6 
(316.2) 
529.2 
(311.6) 
0.052 
a. Data were available for 173 patients: 37 non-relapsers and 136 relapsers.  
b. Antipsychotics medication received over 10 years following the start of randomized trial. 
c. The mean daily dose of each antipsychotic was converted to chlorpromazine equivalent dose. 
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Table 2. Baseline predictors of never relapsing over the 10 years in univariate binary 
logistic regression analyses (P-value ≤ 0.1).   
 
Baseline variablea  
Non-
relapsers 
(n=37) 
Relapsers 
(n=141) 
Univariate 
regression 
Odds ratio (95% CI) 
P value 
Diagnosed with 
schizophrenia spectrum 
disorders,b n (%) 
18 (48.6) 109 (77.3) 0.28 (0.13-0.59) 0.001 
DUP ≤30 days,c n (%) 14 (38) 20 (14) 3.68 (1.63-8.33) 0.002 
PANSS negative 
symptoms  
8.0 (1.4) 9.2 (3.6) 0.85 (0.71-1.01) 0.062 
SANS blunting  0.4 (1.2) 2.7 (5.7) 0.78 (0.61-1.00) 0.046 
SANS sum of all items  1.7 (3.2) 6.7 (14.5) 0.93 (0.86-1.00) 0.057 
Logical memory 
immediate recall (39) 
11.7 (4.5) 8.9 (4.9) 1.13 (1.03-1.24) 0.009 
Logical memory delayed 
recall (43) 
10.1 (4.9) 7.2 (5.4) 1.10 (1.02-1.19) 0.016 
Verbal fluency correct 
recall (41) 
19.9 (6.3) 17.4 (5.5) 1.08 (1.00-1.16) 0.051 
CI, confidence interval; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome 
Scale; SANS, Scale for Assessment of Negative Symptoms. 
a. Unless otherwise specified, values represent means (standard deviation). Number of missing 
observations are shown in brackets.  
b. Diagnosis was categorized into schizophrenia spectrum (including schizophrenia, schizophreniform 
disorder, and schizoaffective disorder [=1]) and non-schizophrenia spectrum (including brief psychotic 
disorder and psychosis not otherwise specified [=2, reference category)).  
c. DUP was classified into ≤30 days (=1) and >30 days (=2, reference category). 
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Table 3. Significant predictors of never relapsing over the 10 years in multivariate 
binary logistic regression analysis (n=137). 
 B SE Wald df P 
value 
Odds Ratio (95% 
CI) 
Diagnosed with 
schizophrenia spectrum 
disorders 
-1.073 0.495 4.704 1 0.030 0.34 (0.13-0.90) 
DUP ≤30 daysa 1.527 0.524 8.506 1 0.004 4.60 (1.65-12.84) 
Logical memory 
immediate recall 
0.098 0.050 3.830 1 0.050 1.10 (1.00-1.22) 
CI, confidence interval; DUP, duration of untreated psychosis. 
a. DUP was classified into ≤30 days (=1) and >30 days (=2, reference category). 
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Table 4. Outcome measures for non-relapsers, relapsers, and all patients. 
 
Outcome variablea 
Non-
relapsers 
(n=30) 
Relapsers 
(n=112) 
All patients 
(n=142) 
P 
value 
Married/stable,b n (%) 13 (43) 23 (21) 37 (26) 0.012 
Diagnosed with schizophrenia 
spectrum disorders, n (%) 
22 (73) 107 (96) 129 (91) <0.001 
Ever alcohol use,c n (%) 20 (69) 62 (57) 82 (59) 0.239 
Ever drug use, n (%) 3 (10) 10 (9) 13 (10) 0.859 
Antipsychotics     
 On clozapine 0 9 (8) 9 (6) 0.109 
 Antipsychotics dose during 
follow-up periodd 
409.1 
(247.0) 
571.7 
(315.3) 
546.1 
(310.4) 
0.027 
 Discontinue medication in 
the 2 years prior to follow-up 
15 (50) 8 (7) 23 (16) <0.001 
Medication compliancee 3.3 (0.6) 3.6 (0.5) 3.5 (0.5) 0.072 
Attitude towards medicationf  3.3 (0.6) 3.3 (0.6) 3.3 (0.6) 0.682 
PANSS     
 Positive  7.5 (1.9) 8.2 (2.9) 8.0 (2.7) 0.098 
 Negative  7.7 (1.3) 8.1 (2.1) 8.0 (2.0) 0.261 
 General psychopathology  18.5 (3.5) 19.1 (3.8) 19.0 (3.8) 0.398 
CDSSg 1.1 (2.6) 1.0 (2.5) 1.0 (2.5) 0.938 
SASh 0 0.009 (0.1) 0.008 (0.1) 0.636 
AIMSi 0 0.2 (1.2) 0.2 (1.0) 0.421 
BARNSj 0 0.4 (1.2) 0.3 (1.1) 0.003 
UKUk     
 Psychic 1.7 (2.3) 2.0 (2.5) 2.0 (2.5) 0.622 
 Neurologic 0.1 (0.2) 0.5 (1.2) 0.5 (1.1) 0.001 
 Autonomic 0.3 (0.6) 0.6 (1.2) 0.6 (1.1) 0.089 
 Others  0.3 (0.8) 0.9 (1.2) 0.8 (1.2) 0.021 
BMIl 23.9 (5.3) 26.9 (5.1) 26.1 (5.4) 0.007 
SOFAS past 1 month 66.4 (9.1) 62.0 (9.1) 63.0 (9.3) 0.019 
Strauss & Carpenter Scalem 3.5 (5.1) 3.2 (0.6) 3.3 (0.6) 0.022 
Months in open employment in 
recent 24 monthsn 
20.4 (7.3) 16.5 (9.1) 17.3 (8.9) 0.020 
PANSS, Positive and Negative Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; 
SAS, Simpson-Angus Scale; AIMS, Abnormal Involuntary Movement Scale; BARNS, Barnes Akathisia 
Rating Scale; UKU, Udvalg for Kliniske Undersøgelser; BMI, Body Mass Index; SOFAS, Social and 
Occupational Functioning Assessment Scale. 
a. Unless otherwise specified, values represent means (standard deviation). Fishers exact test was used 
for cells that have count less than 5. 
b. Data were available in patients who had an end-of-follow-up assessment: 30 non-relapsers, 111 
relapsers, and 141 patients overall. 
c. Schizophrenia spectrum disorders (schizophrenia, schizophreniform disorder, schizoaffective disorder) 
vs. non-schizophrenia spectrum (including psychosis not otherwise specified, brief psychotic disorder, 
delusional disorder). 
d. The mean daily dose of each antipsychotic was converted to a chlorpromazine equivalent dose. Data 
30 
 
were available in patients who had an end-of-follow-up assessment: 21, 112, and 133 patients. 
e. Medication compliance was measured using the modified Adherence Rating Scale. Higher scores 
indicate better adherence behavior. Data were available in patients who had an end-of-follow-up 
assessment: 20, 94, and 114 patients. 
f. Medication attitude was measured using the modified Adherence Rating Scale. Higher scores indicate a 
more positive attitude. Data were available in patients who had an end-of-follow-up assessment: 22, 94, 
and 116 patients. 
g. Data were available in patients who had an end-of-follow-up assessment: 30, 111, and 141 patients. 
h. Data were available in patients who had an end-of-follow-up assessment: 24, 106, and 130 patients. 
i. Data were available in patients who had an end-of-follow-up assessment: 24, 105, and 129 patients.  
j. Data were available in patients who had an end-of-follow-up assessment: 24, 105, and 129 patients. 
k. Data were available in patients who had an end-of-follow-up assessment: 17, 102, and 119 patients. 
l. BMI is the weight in kilograms divided by the square of the height in meters. Data were available in 
patients who had an end-of-follow-up assessment:  28, 103, and 131. 
m. Data were available in patients who had an end-of-follow-up assessment: 30, 106, and 136 patients. 
n. Data were available in patients who had an end-of-follow-up assessment: 28, 107, and 135 patients. 
 
 
 
